Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Yin-Hao
Contact Yin-Hao, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
Targeting SERPINB3–MAPK axis-mediated cuproptosis resistance enhances the response to antitumor immunotherapy - Molecular Cancer
References Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10–45. Google Scholar Cabasag CJ, Arnold M, Rutherford M, Bardot A, Ferlay J, Morgan E, et al. Pancreatic cancer survival by stage and age in seven high-income countries (ICBP SURVMARK-2): a population-based study. Br J Cancer. 2022;126(12):1774–82. Google Scholar Feng Y, Cai L, Pook M, Liu F, Chang CH, Mouti MA, et al.
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer - Molecular Cancer
Human PDAC tissues from Fujian Provincial Hospital, Fujian Medical University Union Hospital and the First Affiliated Hospital of Fujian Medical University were used for IHC, generation of PDOs, RNA-seq and mIHC. Shanghai Outdo Biotech Co., Ltd provided the technical support for mIHC. This study was approved by the Ethics Committee of Fujian Provincial Hospital (Fuzhou, China).
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Yin-Hao
Contact Yin-Hao, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack